Welcome to our dedicated page for Envveno Medical Corporation SEC filings (Ticker: NVNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
enVVeno Medical Corporation’s SEC filings document a medical device issuer developing replacement venous valve technologies for severe deep chronic venous insufficiency. Recent 8-K reports record FDA-related events for the enVVe System and VenoValve, including IDE authorization for the TAVVE pivotal study and disclosures related to VenoValve PMA review outcomes.
The company’s filings also cover capital structure and governance matters, including a one-for-35 reverse stock split, Nasdaq minimum-bid compliance, an at-the-market common stock offering program, annual meeting voting results, director elections, executive-compensation advisory votes, auditor ratification, and proxy materials describing shareholder proposals and regulatory context for the device programs.